CCL5 and cancer: An effective reduction in the migratory and invasive ability along with reduction in the secretory levels of CCL5 protein in MAF than CAF was also observed with both the inhibitors, suggesting the possibility to attenuate the crosstalk between MAF and BRCA1 mutated cancer cells.